https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4487 Wed 11 Apr 2018 15:32:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18773 trend= 0.086). Conclusion: Seasonal fluctuation of MS births as found in this worldwide cohort of patients with MS did not correlate with variation in seasonal fluctuation of UV-light. Most likely, it results from a complex interplay between fluctuation of sunlight, behavioural factors, other environmental factors and (epi)genetic factors.]]> Sat 24 Mar 2018 07:51:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28462 p = 0.02). Furthermore, the outcome of patients negative for CSF-specific OCB was significantly better in comparison to the OCB positive patients, as assessed by Expanded Disability Status Scale change (p < 0.001). Conclusions: The results of this study indicate that latitude could explain some of the inconsistencies in OCB status reported in different populations. The study confirms that OCB positivity in MS is associated with a worse long-term prognosis.]]> Sat 24 Mar 2018 07:39:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27967 Sat 24 Mar 2018 07:38:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30017 Sat 24 Mar 2018 07:28:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42843 n = 195; untreated n = 338). Median on-study pairwise-censored follow-up was 3.4 years (quartiles 1.2–5.5). No difference in the hazard of experiencing 3-month confirmed EDSS progression events was observed between the groups [hazard ratio (HR), 1.0; 95% confidence interval (CI), 0.6–1.7, P = 0.87]. We did not find significant differences in the hazards of confirmed EDSS improvement (HR, 1.0; 95% CI, 0.6–1.6, P = 0.91) or reaching a confirmed EDSS step ≥7 (HR, 1.1; 95% CI, 0.7–1.6, P = 0.69). Conclusion: Our pooled analysis of disease-modifying agents suggests that these therapies have no substantial effect on short- to medium-term disability outcomes in PPMS.]]> Mon 05 Sep 2022 14:44:21 AEST ]]>